Nd:YAG Laser Effects on Subgingival Microbiota in Stage III-IV Periodontitis (NCT07061756) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Nd:YAG Laser Effects on Subgingival Microbiota in Stage III-IV Periodontitis
China240 participantsStarted 2024-08-28
Plain-language summary
This randomized controlled trial (RCT) aims to evaluate the clinical efficacy of Nd:YAG laser adjunctive therapy and its impact on the subgingival microbiome in patients with stage III-IV periodontitis. The study addresses two key questions: (1) Whether Nd:YAG laser combined with scaling and root planing (SRP) yields significantly greater improvements in periodontal parameters compared to SRP alone; and (2) How subgingival microbial dynamics correlate with therapeutic outcomes.
Participants were randomized into two groups: the SRP group (mechanical debridement only) and the Nd group (mechanical debridement with Nd:YAG laser therapy). Clinical parameters-including probing depth (PD), clinical attachment level (CAL), and gingival index (GI)-were assessed at baseline and 3 months post-treatment. Subgingival plaque samples were analyzed via 16S rDNA sequencing to characterize microbial community shifts.
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Aged 18-80 years
* Minimum of 14 remaining natural teeth
* Diagnosis of Stage III-IV periodontitis according to the 2018 World Workshop classification system
* No periodontal treatment within the past 6 months
* Willing to provide informed consent and participate in the study protocol
Exclusion Criteria:
* Presence of systemic conditions that may affect periodontal treatment outcomes (e.g., uncontrolled hypertension \[\>140/90 mmHg\], diabetes mellitus \[HbA1c \>7%\])
* Use of antibiotics or medications known to induce gingival enlargement (e.g., calcium channel blockers, phenytoin) within the past 3 months
* Coagulation disorders or hematologic diseases
* Active systemic infections
* Pregnancy or lactation
* Acute periodontal lesions
* Inability to comply with study protocols
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Alpha diversity of subgingival microbiota
Timeframe: From enrollment to the end of treatment at 3 months
2
Probing Depth
Timeframe: From enrollment to the end of treatment at 3 months